<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450943</url>
  </required_header>
  <id_info>
    <org_study_id>SURG-005-10S</org_study_id>
    <secondary_id>11-04-00618</secondary_id>
    <nct_id>NCT01450943</nct_id>
  </id_info>
  <brief_title>VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic</brief_title>
  <acronym>DOLCE</acronym>
  <official_title>A Comparative Efficacy Study: Treatments of Non-Healing Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Northern California Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effectiveness of cellular dermal
      replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing
      diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2011</start_date>
  <completion_date type="Actual">April 4, 2018</completion_date>
  <primary_completion_date type="Actual">December 14, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Closure by Week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>The primary outcome of interest is defined as the wound healed completely on or before visit 15, regardless of a later recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Closure at 20 Weeks</measure>
    <time_frame>20 weeks</time_frame>
    <description>Complete wound closure at study endpoint. The Secondary outcome of interest is defined as the wound healed completely on or before visit 19, regardless of a later recurrence. The number of subjects analyzed at secondary outcome differs from primary outcome due to some subjects not completing the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dermagraft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SECONDARY dressing gauze and tape</intervention_name>
    <description>SECONDARY dressing gauze and tape</description>
    <arm_group_label>Dermagraft</arm_group_label>
    <arm_group_label>Oasis</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>debridement, irrigation</intervention_name>
    <description>debridement, irrigation</description>
    <arm_group_label>Dermagraft</arm_group_label>
    <arm_group_label>Oasis</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermagraft</intervention_name>
    <description>Dermagraft per company protocol</description>
    <arm_group_label>Dermagraft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oasis</intervention_name>
    <description>Oasis per company protocol</description>
    <arm_group_label>Oasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Answering NO will exclude patient):

          -  An Institutional Review Board (IRB) Informed Consent Form signed and dated prior to
             any study-related activities.

          -  The area of the study ulcer after debridement is between 1 cm2 and 25 cm2 at Visit
             3/Week 0.

          -  Subjects between 18 and 85 years of age.

          -  Subject's highest Ankle-Brachial Pressure Index (ABPI) / Ankle-Arm Index (AAI) is
             greater than or equal to 0.80 and lower than 1.4 (the highest ABPI/AAI value from
             three measurements within last 6 months shall apply).or a toe-arm index is equal to or
             higher than 0.6.

          -  The patient has one or more diabetic ulcers on the target foot with only one ulcer
             selected as the study (target) ulcer. The target ulcer must be at least 4 cm from a
             non-target ulcer and in the Investigator's opinion, be unlikely to coalesce with
             another ulcer within 12 weeks of randomization.

          -  Subject's study ulcer is full thickness and does not extend to bone, muscle, or
             tendon.

          -  Subject's study ulcer has been present at least 4 weeks prior to the initial screening
             (Visit 1) or 6 weeks at randomization (Visit 3).

          -  Subject has been diagnosed with Type 1 or Type 2 diabetes and HbA1c is less than 10%.

          -  Study ulcer has no clinical feature of infection (2 signs of inflammation and elevated
             bacterial load of the wound).

          -  For female subjects of childbearing age potential, the subject has a negative
             pregnancy test and is not lactating for the duration of the study.

          -  Subject understands the requirements of this study and is willing to comply with all
             the study requirements.

        Exclusion Criteria:

        (Answering YES will exclude patient):

          -  The subject is diagnosed with cancer and is undergoing treatment with
             immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids
             less than 30 days before enrollment.

          -  The subject is diagnosed with HIV/AIDS.

          -  The subject is diagnosed with any bleeding disorders.

          -  The subject is diagnosed with any connective tissue diseases.

          -  For female subjects, the subject is pregnant or lactating.

          -  The subject has a history of illicit drug use within one year of enrollment.

          -  In the past year, the subject experiences episodes of drinking more than 5 alcoholic
             beverages in less than two hours and/or drinking alcohol has become a problem in
             interpersonal relationships, work, driving and/or their behavior in general.

          -  The subject has any active infected wounds or osteomyelitis (confirmed by bone biopsy,
             MRI or bone scan).

          -  Doppler exam within the last 365 days demonstrating reflux greater than 0.5 seconds.

          -  The subject is diagnosed with active Charcot as described by Saunder's classification
             system.

          -  The subject manifests signs of poor nutritional status and/or albumin level &lt; 2.9.

          -  The subject has been exposed to Dermagraft and/or Oasis in the last 60 days.

          -  The study ulcer size is less than 0.5 cm2 or greater than 25 cm2.

          -  The subject has any porcine allergy or cow product allergy.

          -  The subject's recent (last 30 days) chemistry tests serum creatinine is 2 times above
             the upper limit of normal and/or LFT's 3 times above the upper limit of normal.

          -  Between Visit 1/Week -2 and Visit 3/Week 0 (randomization) the study ulcer has
             decreased in size by more than 40%, or increased in size by more than 50%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rivkah R. Isseroff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Northern California Health Care System, Mather, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Northern California Health Care System, Mather, CA</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>July 31, 2019</results_first_submitted>
  <results_first_submitted_qc>August 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>Chronic wounds</keyword>
  <keyword>Chronic ulcers</keyword>
  <keyword>Oasis</keyword>
  <keyword>Dermagraft</keyword>
  <keyword>Adaptic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01450943/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>120 subjects enrolled from which 2 study subjects were not randomized into any groups and were terminated from the study; therefore, we only had overall of 118 study subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Consist of subjects who were randomized to treatment with standard of Care (SOC) which included debridement, irritation, primary dressing, Adaptic, secondary dressing gauze and tape.</description>
        </group>
        <group group_id="P2">
          <title>Dermagraft</title>
          <description>These are study subject who were randomized to treatment arm with Dermagraft. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute composed of viable newborn foreskin fibroblasts, seeded onto a bio-absorbable polyglactin mesh.
The treatment included debridement, irrigation, primary dressing and Dermagraft and Adaptic, and secondary dressing with gauze and tape.
Dermagraft placed per company protocol</description>
        </group>
        <group group_id="P3">
          <title>Oasis</title>
          <description>These are study subject who were randomized to treatment arm with Oasis. Oasis is a bio-absorbable ECM derived from porcine small intestinal submucosa. the product is processed using proprietary methods to retain its original structure while stored at room temperature.
The treatment included debridement, irrigation, primary dressing and Oasis and Adaptic, and secondary dressing with gauze and tape.
Oasis placed per company protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure, loss to follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Veteran subject patient population</population>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Consist of subjects who were randomized to treatment with standard of Care (SOC) which included debridement, irritation, primary dressing, Adaptic, secondary dressing gauze and tape.</description>
        </group>
        <group group_id="B2">
          <title>Dermagraft</title>
          <description>Study subjects who were randomized to treatment arm with Dermagraft. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute composed of viable newborn foreskin fibroblasts, seeded onto a bio-absorbable polyglactin mesh.
The treatment included debridement, irrigation, primary dressing and Dermagraft and Adaptic, and secondary dressing with gauze and tape.
Dermagraft placed per company protocol</description>
        </group>
        <group group_id="B3">
          <title>Oasis</title>
          <description>Study subjects who were randomized to treatment arm with Oasis. Oasis is a bio-absorbable ECM derived from porcine small intestinal submucosa. the product is processed using proprietary methods to retain its original structure while stored at room temperature.
The treatment included debridement, irrigation, primary dressing and Oasis and Adaptic, and secondary dressing with gauze and tape.
Oasis placed per company protocol</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="48"/>
            <count group_id="B4" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.31" spread="9.09"/>
                    <measurement group_id="B2" value="62.83" spread="9.3"/>
                    <measurement group_id="B3" value="61.88" spread="8.64"/>
                    <measurement group_id="B4" value="62.67" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Study subjects information was directly obtained from the individuals and/or patient medical records</description>
          <population>Northern California veteran patient population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Analyzed participants</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Analyzed participants</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Analyzed participants</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.52" spread="6.59"/>
                    <measurement group_id="B2" value="32.44" spread="5.32"/>
                    <measurement group_id="B3" value="36.51" spread="11.55"/>
                    <measurement group_id="B4" value="35.15" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Closure by Week 15</title>
        <description>The primary outcome of interest is defined as the wound healed completely on or before visit 15, regardless of a later recurrence.</description>
        <time_frame>15 weeks</time_frame>
        <population>Primary Outcome results consist of data available for the Northern California Veteran patient population participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Consist of subjects who were randomized to treatment with standard of Care (SOC) which included debridement, irritation, primary dressing, Adaptic, secondary dressing gauze and tape without any grafts.</description>
          </group>
          <group group_id="O2">
            <title>Dermagraft</title>
            <description>Study subjects who were randomized to treatment arm with Dermagraft. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute composed of viable newborn foreskin fibroblasts, seeded onto a bio-absorbable polyglactin mesh.
The treatment included debridement, irrigation, primary dressing and Dermagraft and Adaptic, and secondary dressing with gauze and tape.
Dermagraft placed per company protocol</description>
          </group>
          <group group_id="O3">
            <title>Oasis</title>
            <description>Study subjects who were randomized to treatment arm with Oasis. Oasis is a bio-absorbable ECM derived from porcine small intestinal submucosa. the product is processed using proprietary methods to retain its original structure while stored at room temperature.
The treatment included debridement, irrigation, primary dressing and Oasis and Adaptic, and secondary dressing with gauze and tape.
Oasis placed per company protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Closure by Week 15</title>
          <description>The primary outcome of interest is defined as the wound healed completely on or before visit 15, regardless of a later recurrence.</description>
          <population>Primary Outcome results consist of data available for the Northern California Veteran patient population participants who completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not Healed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Healed completely</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0517</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.712595</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9141</ci_lower_limit>
            <ci_upper_limit>8.4839</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wound Closure at 20 Weeks</title>
        <description>Complete wound closure at study endpoint. The Secondary outcome of interest is defined as the wound healed completely on or before visit 19, regardless of a later recurrence. The number of subjects analyzed at secondary outcome differs from primary outcome due to some subjects not completing the study.</description>
        <time_frame>20 weeks</time_frame>
        <population>Primary Outcome results consist of data still available for the Veteran patient population participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Consist of subjects who were randomized to treatment with standard of Care (SOC) which included debridement, irritation, primary dressing, Adaptic, secondary dressing gauze and tape.</description>
          </group>
          <group group_id="O2">
            <title>Dermagraft</title>
            <description>Study subjects who were randomized to treatment arm with Dermagraft. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute composed of viable newborn foreskin fibroblasts, seeded onto a bio-absorbable polyglactin mesh.
The treatment included debridement, irrigation, primary dressing and Dermagraft and Adaptic, and secondary dressing with gauze and tape.
Dermagraft placed per company protocol</description>
          </group>
          <group group_id="O3">
            <title>Oasis</title>
            <description>Study subjects who were randomized to treatment arm with Oasis. Oasis is a bio-absorbable ECM derived from porcine small intestinal submucosa. the product is processed using proprietary methods to retain its original structure while stored at room temperature.
The treatment included debridement, irrigation, primary dressing and Oasis and Adaptic, and secondary dressing with gauze and tape.
Oasis placed per company protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Closure at 20 Weeks</title>
          <description>Complete wound closure at study endpoint. The Secondary outcome of interest is defined as the wound healed completely on or before visit 19, regardless of a later recurrence. The number of subjects analyzed at secondary outcome differs from primary outcome due to some subjects not completing the study.</description>
          <population>Primary Outcome results consist of data still available for the Veteran patient population participants who completed the study.</population>
          <units>Wound Closure in weeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not healed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Healed completely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7974</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.812339</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2543</ci_lower_limit>
            <ci_upper_limit>2.5224</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Effectiveness</title>
        <time_frame>12 weeks</time_frame>
        <population>Data not available because the investigators did not asses the cost effectiveness for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>SOC Group:
debridement, irrigation , PRIMARY dressing and Adaptic, SECONDARY dressing gauze and tape
SECONDARY dressing gauze and tape: SECONDARY dressing gauze and tape
debridement, irrigation: debridement, irrigation</description>
          </group>
          <group group_id="O2">
            <title>Dermagraft</title>
            <description>Dermagraft Group: debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
SECONDARY dressing gauze and tape: SECONDARY dressing gauze and tape
debridement, irrigation: debridement, irrigation
Dermagraft: Dermagraft per company protocol</description>
          </group>
          <group group_id="O3">
            <title>Oasis</title>
            <description>Oasis Group:
debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
SECONDARY dressing gauze and tape: SECONDARY dressing gauze and tape
debridement, irrigation: debridement, irrigation
Oasis: Oasis per company protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Effectiveness</title>
          <population>Data not available because the investigators did not asses the cost effectiveness for the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Visits 1-2: consent and screen the subject. Obtain medical history, vitals, concomitant medications, and adverse events recorded. Visit 3: If after two weeks, the subject qualifies to continue, the subject is randomized into one of three groups. Visits 4-15: Subjects follow up weekly for study visit which includes wounds undressed, assessed, cleaned and debrided, traced, photographed, and redressed again. Visit 16-19: These are the follow-up visits. There will be 4 visits spread over 16 weeks.</time_frame>
      <desc>Adverse events were collected through the patient and/or through patient chart review.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Consist of subjects who were randomized to treatment with standard of Care (SOC) which included debridement, irritation, primary dressing, Adaptic, secondary dressing gauze and tape.</description>
        </group>
        <group group_id="E2">
          <title>Dermagraft</title>
          <description>Study subjects who were randomized to treatment arm with Dermagraft. Dermagraft is a cryopreserved human fibroblast-derived dermal substitute composed of viable newborn foreskin fibroblasts, seeded onto a bio-absorbable polyglactin mesh.
The treatment included debridement, irrigation, primary dressing and Dermagraft and Adaptic, and secondary dressing with gauze and tape.
Dermagraft placed per company protocol</description>
        </group>
        <group group_id="E3">
          <title>Oasis</title>
          <description>Study subjects who were randomized to treatment arm with Oasis. Oasis is a bio-absorbable ECM derived from porcine small intestinal submucosa. the product is processed using proprietary methods to retain its original structure while stored at room temperature.
The treatment included debridement, irrigation, primary dressing and Oasis and Adaptic, and secondary dressing with gauze and tape.
Oasis placed per company protocol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Non-study related</sub_title>
                <description>Cardiac, acute cholecystitis, suicide ideation</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Involved study related foot ulcer</sub_title>
                <description>Infection that require in patient IV treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-study related</sub_title>
                <description>Cardiac, Acute cholecystitis, infections</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sara Dahle, D.P.M., M.P.H.</name_or_title>
      <organization>VA Northern California Health Care System</organization>
      <phone>916-843-7151</phone>
      <email>Sara.dahle@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

